## Will my privacy be protected?

All personal and medical information will be kept strictly confidential. Information about your health while you are enrolled in the YORVIPATH Pregnancy Safety Study will be kept anonymous and any identifying information will not be used.

## What will my participation involve once I am enrolled?

About 50 women across the US will participate in this study. Your participation may last up to 21 months in total: 9 months during pregnancy and 12 months after your baby is born.

You will be contacted once per trimester, at the estimated date of delivery, and when your baby is 3, 6, 9 and 12 months of age to provide routine information about your pregnancy and your baby's health. At each time point you will be asked to confirm your contact information.

## Risks/Benefits:

YORVIPATH is an FDA-approved treatment for hypoparathyroidism in adults. However there is not enough information yet to establish the safety of Yorvipath in pregnancy. This registry helps gather important information about its use during pregnancy to better understand effects on mothers and babies. For more information on YORVIPATH please refer to the prescribing information that comes with your medication.

To speak to a study representative, contact the YORVIPATH Pregnancy Safety Study toll-free at: 877-229-2184 M-F, 8-8 ET or via email at Yorvipathpregnancy@ubc.com.

For more information visit:
**www.YORVIPATHregistry.com**

ascendis pharma

MED-US-TC-PTH-2600005
01/2026

**YORVIPATH Pregnancy Safety Study**

# Patient Brochure

YourLifePath
PREGNANCY REGISTRY

## YORVIPATH® (Palopegteriparatide) Pregnancy Safety Study

This study is being done to learn more about how taking YORVIPATH during pregnancy or while breastfeeding may affect the health of women, babies in the womb and infants after birth.

This is an observational study which means you and your baby will continue to receive the usual medical care from your own doctors. This study does not require any extra visits, tests, or procedures.

## Why should I participate in this study?

Your participation is voluntary but may help doctors and researchers better understand the safety of YORVIPATH and may help guide future care for pregnant women and babies.

You may also receive compensation after each completed data collection timepoint.

YourLifePath
PREGNANCY REGISTRY

## Who can participate in the study?

This study is for women, aged 15-50 years, who took YORVIPATH within 15 days before becoming pregnant or who took this medication any time during their pregnancy.

During the study the following information will be collected:

- Medical history
- Information about your pregnancy
- Estimated delivery date
- Any complications during your pregnancy
- Medications taken during your pregnancy
- Intake of alcohol/drugs and smoking Status

The following information will be collected after you have given birth:

- Information about your delivery including any complications
- Your newborn(s) (e.g. gender, birth weight and length)
- Any breastfeeding complications to you or your newborn after the word complications

The following information will be collected about your child until 12 months of age:

- Illnesses and diseases
- Growth and development
- Breastfeeding status

## How do I enroll?

To learn more about the YORVIPATH Pregnancy Safety Study and to find out if you are eligible for enrollment, contact a study representative at **877-229-2184**, or by email at Yorvipathpregnancy@ubc.com or visit the study website at: YORVIPATHregistry.com. You may also ask your doctor to enroll you.

If you are eligible and decide to take part, you will be asked to review and sign an informed consent form. This form shows that you understand the study and agree to participate. This provides your permission for your personal and infant's healthcare information to be collected. After consent is received a study representative will contact your doctor to confirm your personal health information.